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Abstract 
Background: Bisphosphonate-related osteonecrosis is an infrequent but potentially serious complication. Its treat-
ment remains complex, and in some cases can be mutilating. Prevention, a correct diagnosis and opportune man-
agement are crucial.
Material and Methods: A cross-sectional study was made, interviewing 410 dentists with the aim of assessing their 
knowledge of the subject.
Results: Practically all of the dental professionals (99.7%) were found to lack sufficient knowledge of the preven-
tion, diagnosis and management of bisphosphonate-related osteonecrosis.
Conclusions: Actions including increased diffusion in the professional media and inclusion of the subject in train-
ing programs are needed in order to enhance the knowledge of bisphosphonate-related osteonecrosis among den-
tists and thus prevent complications in this group of patients.
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Introduction
Bisphosphonates are drugs used to prevent and treat 
certain bone disorders, including osteoporosis / osteo-
penia, multiple myeloma, bone metastases associated to 
certain types of cancer, hypercalcemia, Paget’s disease, 
etc. (1). The first therapeutic bisphosphonate was etid-
ronate, introduced on the market in 1960 for the man-
agement of Paget’s disease. The mechanism of action of 
these drugs involves the induction of osteoclast apop-
tosis, resulting in the inhibition of bone reabsorption. 
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Many agents belonging to this drug group are currently 
available in Mexico, and they are widely used in differ-
ent medical specialties (2,3). In 2003, Marx published 
the first report associating bisphosphonate use to the 
exposure of maxillary bone, one year later Ruggiero 
published a series of 63 patients with bisphosphonate-
related osteonecrosis of the jaws (BRONJ) (4). Since 
then, disorders of this kind have been widely reported 
in the medical and dental literature.
On entering the key word “bisphosphonate-related os-
teonecrosis”, specialized scientific search tools such 
as PubMed currently yield over 960 articles referred 
to this topic. Even non-specialized popular websites 
such as Wikipedia mention the risk of osteonecrosis 
of the jaws associated to the use of bisphosphonates. 
Bisphosphonate-related osteonecrosis is an infrequent 
but potentially serious problem (1,4). Its treatment re-
mains complex, and in some cases can be aggressive 
and mutilating (5,6). Despite the extensive scientific 
and non-scientific literature on the subject, many Mexi-
can physicians and dentists lack the knowledge about 
bisphosphonate-related osteonecrosis, or underestimate 
its risks - a fact that can have important consequences 
for patient health.
The present study was carried out to evaluate the knowl-
edge of bisphosphonate-related osteonecrosis among 
Mexican dentists, including its risk factors and manage-
ment options, with a view to defining proper strategies 
capable of reducing the frequency of this complication.
Material and Methods
A cross-sectional study was made, interviewing a prob-
abilistic sample of 410 dentists with the aim of assessing 
their knowledge of the subject. The dental professionals 
came from both private and public general or specialized 
practice in 25 states of the country. The questionnaire 
was divided into areas. A first area addressed general in-
formation on the dental professionals: training, speciali-
zation (if any), type of practice, years of professional ex-
perience, participation in updating training courses, the 
Mexican state in which professional practice is carried 
out, membership in associations or specialized boards, 
and teaching activities. A second area wash focused to 
assess the degree of knowledge about bisphosphonate-
related osteonecrosis, the questionnaire asked about the 
therapeutic indications of bisphosphonates, the drug 
substances involved, brand names, risk factors, the di-
agnostic criteria and treatment options. Lastly, a third 
area was used to asses a clinical case involving a pa-
tient receiving bisphosphonate treatment and requiring 
dental extraction. The answers obtained were evaluated 
by experts, based on the most recent literature on the 
subject. The study was reviewed and approved by the 
institutional ethics committee and written consent was 
obtained for all the participants in the study.
Results
A total of 410 interviews were carried out among dentists 
from 25 states throughout the country – the predominant 
settings being Mexico City (n = 134; 32.7%) and Mexico 
state (n = 148; 36.1%). A total of 249 dentists (60.7%) were 
dedicated to general practice, 122 (29.8%) were special-
ists, 36 (8.8%) had training at master degree level, and 
three (0.7%) held a PhD. The distribution by specialties 
was as follows: orthodontics 67 (16.3%), prosthodontics 
and oral rehabilitation 22 (5.4%), pediatric dentistry 18 
(4.4%), endodontics 14 (3.4%),  maxillofacial surgery 13 
(3.2%), periodontics 9 (2.2%) oral medicine 4 (1%) and 
others 10 (2.4%). Of those interviewed 71% were dedicat-
ed to private practice, 15% to public practice, and 13.4% 
to both. Only 34% reported being affiliated to some as-
sociation or specialized board. With regard to teaching 
activities, 115 of the professionals (28%) were or had 
been involved in academic activities. In turn, 215 of the 
dentists (52%) reported having attended between 1-5 con-
gresses during the last 5 years.
The findings referred to general knowledge of bisphos-
phonates and bisphosphonate-related osteonecrosis are 
shown in table 1.
The findings referred to knowledge of diagnostic cri-
Items related to knowledge of bisphosphonates Responses (n-410)
Familiarization with the term bisphosphonate-related 
osteonecrosis
Yes -166 (40.5%)
No - 244 (59.5%)
Citation of at least one disease in which bisphosphonates 
are used
No disease cited
263 (64.1%)
147 (35.9%)
Citation of at least one bisphosphonate drug substance
No drug product cited
101 (24.6%)
309 (75.4%)
Citation of at least one bisphosphonate brand name
No brand name cited
65 (15.9%)
345 (84.1%)
Table 1. General questionnaire items referred to bisphosphonates and bisphosphonate-related 
osteonecrosis.
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teria, risk factors and treatment options in bisphospho-
nate-related osteonecrosis are shown in table 2.
Regarding assessment of the clinical case presented in 
Items related to knowledge of the diagnosis, risk factors and 
treatment of bisphosphonate-related osteonecrosis Responses (n=410)
One diagnostic criterion cited 40 (9.8%)
Two diagnostic criteria cited 6 (1.5%)
Three diagnostic criteria cited 2 (0.5%)
No diagnostic criterion cited 362 (88.2%)
At least one risk factor cited 56 (13.7%)
Two risk factors cited 33 (8%)
No risk factor cited 321 (78.2%)
Three correct treatments cited 5 (1.2%)
Table 2. Level of knowledge among the dentists referred to diagnostic criteria, risk factors and treat-
ment options in bisphosphonate-related osteonecrosis.
the questionnaire, 140 of the dentists (32.2%) stated that 
they would perform extraction (90 with prior antibiotic 
administration and 50 without), 92 (22.4%) would not 
perform extraction, and 166 (40.5%) would refer the pa-
tient to specialized care. These data were statistically 
significant (p=0.01).
Specific criteria applied to the answers were established 
to determine how many of those interviewed had suf-
ficient knowledge of the subject and could adequately 
treat a patient receiving or having received bisphospho-
nates. In this regard, 407 (99.3%) of the professionals 
were found to lack sufficient knowledge of the preven-
tion, diagnosis and management of bisphosphonate-
related osteonecrosis, and only three (0.7%) met the 
established criteria. These three professionals were 
specialized in maxillofacial surgery, oral medicine and 
periodontics, respectively.
Discussion
The results obtained in our study are a reason for con-
cern, since they indicate that practically all of the dental 
professionals (99.7%) lacked sufficient knowledge for 
the adequate diagnosis and management of patients re-
ceiving bisphosphonates and who require dental care.
In similar studies   conducted in other countries, Yoo et 
al. in Korea found 56.5% of a series of 254 dentists to be 
familiarized with bisphosphonate-related osteonecro-
sis, and 31.4% recorded patient antecedents referred to 
these drugs in the clinical history. The authors found 
that most of those interviewed were not aware of the 
guidelines of the American Association of Oral and 
Maxillofacial Surgeons (7). In Ontario (Canada), Al-
hussain et al. found 60% of the dentists interviewed 
to have adequate knowledge of bisphosphonate-related 
osteonecrosis. On the other hand, 50% of the profes-
sionals did not feel comfortable treating patients using 
bisphosphonates, and 23% claimed to follow the pub-
lished guidelines referred to surgical treatment (8).
An interesting observation in our study is the fact that 
although 166 (40.5%) of those interviewed claimed to be 
familiarized with the term “bisphosphonate-related os-
teonecrosis”, and 144 (34%) reported having read some 
article or attended some conference on the subject, only 
3 (0.7%) of the dental professionals actually demon-
strated sufficient knowledge in this field.
Of the global participants in the study, 140 (34.1%) re-
ported that they would perform tooth extraction in a pa-
tient receiving bisphosphonates - a situation that would 
pose a risk of developing osteonecrosis. Considering 
that drugs of this kind are widely used in the general 
population, these findings indicate that a relevant pro-
portion of individuals subjected to oral surgical proce-
dures would be at risk of developing osteonecrosis. This 
situation may not have serious consequences if correct 
diagnosis is established and adequate treatment is pro-
vided; however, if the diagnosis is delayed or further 
surgical procedures are carried out, the consequences 
for the patient may prove to be serious - with important 
expenditure in terms of healthcare costs and resources.
Of the professionals who answered that they would per-
form extraction, 80 (57%) were general dentists and 22 
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(15.7%) were orthodontists. This suggests that dentists 
lacking postgraduate training have even less knowledge 
in this area.
It is crucial to analyze why we have such poor results 
in this field in our country, in order to adopt corrective 
measures and avoid complications in patients at risk. 
An important aspect is the lack of specialization and 
postgraduate training. The dental professional census in 
Mexico corresponding to 2010 reflected the existence 
of 151,622 dentists, of which only 6.5% had specialized 
training, and 0.75% and 0.035% held a master degree 
and PhD, respectively (9). The percentage of dentists 
with postgraduate training is clearly very low. Another 
important factor is the lack of attending to updating 
courses. In effect, we found that 59% of those inter-
viewed attended less than one congress a year during 
the last 5 years, and 5% claimed that did not attended 
any such congresses at all. Lastly, another significant 
element to be considered would be the number of scien-
tific articles read by the dental professionals, though we 
lacked data to explore this factor.
Conclusions
The results of our study reveal very limited knowledge 
of bisphosphonate-related osteonecrosis among Mexi-
can dentists. In effect, a full 99.3% of those interviewed 
did not have sufficient knowledge regarding drugs, di-
agnosis and treatment in this field – a fact that could 
pose an important problem for patients at risk. In our 
opinion, the situation could be improved through in-
creased diffusion of the subject at congresses and sci-
entific events; communications issued by the health 
institutions or dental associations; and the inclusion of 
bisphosphonate-related osteonecrosis in both pre- and 
postgraduate training programs. We also consider it 
advisable for dental professionals to document bisphos-
phonate use in the clinical history – questioning their 
patients directly in this regard.
On the basis of the results obtained, we consider it im-
portant to conduct similar studies targeted to general 
and specialized physicians who prescribe these drugs, in 
order to evaluate their knowledge in the field and know 
whether or not they adequately warn their patients on 
the oral cavity risks involved.
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